www.jobs4dd.com
Seattle Genetics (Bothell, Washington) has begun a Phase IIb clinical trial of its monoclonal antibody SGN-40 as an adjunct to second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Under the terms of its worldwide collaboration agreement with Genentech, Seattle Genetics will receive a $12 million milestone payment for starting the study.
The randomised, double-blind, placebo-controlled trial – named SeaGen MARINER - is expected to enroll approximately 200 patients at around 60 sites worldwide. Patients will receive either Rituxan (rituximab), ifosfamide or carboplatin and etoposide (R-ICE) plus SGN-40, or R-ICE plus placebo. The primary endpoint is complete response rate. Additional endpoints include safety, tolerability, failure-free and overall survival.
SGN-40 is a humanised mAb that targets the CD40 antigen, which is expressed on most B lineage haematologic malignancies, including non-Hodgkin’
In addition to the SeaGen MARINER trial, a Phase II single-agent trial of SGN-40 in DLBCL and a phase Ib trial of SGN-40 in combination with Revlimid (lenalidomide)
“We are moving forward with this global trial based on the encouraging safety profile and clinical activity observed in our phase I single-agent trial in patients with DLBCL, together with preclinical data demonstrating enhanced efficacy of SGN-40 when combined with chemotherapy,”
Photo:
http://www.prlog.org/
